0
     

Report Added
Report already added
North America (NAFTA) Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

North America (NAFTA) Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $77,821.8 million in 2021.The Mexico was the fastest growing country, with a CAGR of 5.2% over the 2017-21 period.
- Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $65,015.6 million in 2021. This was followed by Mexico and Canada, with a value of $6,849.9 and $5,956.3 million, respectively.
- The US is expected to lead the generics industry in the NAFTA bloc, with a value of $71,626.7 million in 2026, followed by Mexico and Canada with expected values of $8,504.7 and $6,774.9 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
- Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
- Compares data from the US, Canada and Mexico, alongside individual chapters on each country

Reasons to Buy

- What was the size of the NAFTA generics market by value in 2021?
- What will be the size of the NAFTA generics market in 2026?
- What factors are affecting the strength of competition in the NAFTA generics market?
- How has the market performed over the last five years?
- How large is the NAFTA generics market in relation to its regional counterparts?

Table of Contents

1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Generics
2.1. Industry Outlook
3 Generics in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Generics in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Company Profiles
10 Appendix
10.1. Methodology
10.2. About MarketLine

List of Tables
Table 1: NAFTA countries generics industry, revenue ($m), 2017-26
Table 2: NAFTA countries generics industry, revenue ($m), 2017-21
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2021-26
Table 4: Canada generics market value: $ million, 2016-21
Table 5: Canada generics market volume: %, 2016-21
Table 6: Canada generics market geography segmentation: $ million, 2021
Table 7: Canada generics market value forecast: $ million, 2021-26
Table 8: Canada generics market volume forecast: %, 2021-26
Table 9: Canada size of population (million), 2017-21
Table 10: Canada gdp (constant 2005 prices, $ billion), 2017-21
Table 11: Canada gdp (current prices, $ billion), 2017-21
Table 12: Canada inflation, 2017-21
Table 13: Canada consumer price index (absolute), 2017-21
Table 14: Canada exchange rate, 2017-21
Table 15: Mexico generics market value: $ million, 2016-21
Table 16: Mexico generics market volume: %, 2016-21
Table 17: Mexico generics market geography segmentation: $ million, 2021
Table 18: Mexico generics market value forecast: $ million, 2021-26
Table 19: Mexico generics market volume forecast: %, 2021-26
Table 20: Mexico size of population (million), 2017-21
Table 21: Mexico gdp (constant 2005 prices, $ billion), 2017-21
Table 22: Mexico gdp (current prices, $ billion), 2017-21
Table 23: Mexico inflation, 2017-21
Table 24: Mexico consumer price index (absolute), 2017-21
Table 25: Mexico exchange rate, 2017-21
Table 26: United States generics market value: $ billion, 2016-21
Table 27: United States generics market volume: %, 2016-21
Table 28: United States generics market geography segmentation: $ billion, 2021
Table 29: United States generics market value forecast: $ billion, 2021-26
Table 30: United States generics market volume forecast: %, 2021-26
Table 31: United States size of population (million), 2017-21
Table 32: United States gdp (constant 2005 prices, $ billion), 2017-21
Table 33: United States gdp (current prices, $ billion), 2017-21
Table 34: United States inflation, 2017-21
Table 35: United States consumer price index (absolute), 2017-21
Table 36: United States exchange rate, 2017-21
Table 37: Apotex, Inc.: key facts
Table 38: Apotex, Inc.: Key Employees
Table 39: Sun Pharmaceutical Industries Ltd: key facts
Table 40: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 41: Sun Pharmaceutical Industries Ltd: Key Employees
Table 42: Sun Pharmaceutical Industries Ltd: Key Employees Continued
Table 43: Aurobindo Pharma Ltd: key facts
Table 44: Aurobindo Pharma Ltd: Annual Financial Ratios
Table 45: Aurobindo Pharma Ltd: Key Employees
Table 46: Teva Pharmaceutical Industries Limited: key facts
Table 47: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 48: Teva Pharmaceutical Industries Limited: Key Employees
Table 49: Viatris Inc.: key facts
Table 50: Viatris Inc.: Annual Financial Ratios
Table 51: Viatris Inc.: Key Employees
Table 52: Viatris Inc.: Key Employees Continued
Table 53: Pfizer Inc.: key facts
Table 54: Pfizer Inc.: Annual Financial Ratios
Table 55: Pfizer Inc.: Key Employees
Table 56: Pfizer Inc.: Key Employees Continued

List of Figures
Figure 1: NAFTA countries generics industry, revenue ($m), 2017-26
Figure 2: NAFTA countries generics industry, revenue ($m), 2017-21
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2021-26
Figure 4: Canada generics market value: $ million, 2016-21
Figure 5: Canada generics market volume: %, 2016-21
Figure 6: Canada generics market geography segmentation: % share, by value, 2021
Figure 7: Canada generics market value forecast: $ million, 2021-26
Figure 8: Canada generics market volume forecast: %, 2021-26
Figure 9: Forces driving competition in the generics market in Canada, 2021
Figure 10: Drivers of buyer power in the generics market in Canada, 2021
Figure 11: Drivers of supplier power in the generics market in Canada, 2021
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2021
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2021
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2021
Figure 15: Mexico generics market value: $ million, 2016-21
Figure 16: Mexico generics market volume: %, 2016-21
Figure 17: Mexico generics market geography segmentation: % share, by value, 2021
Figure 18: Mexico generics market value forecast: $ million, 2021-26
Figure 19: Mexico generics market volume forecast: %, 2021-26
Figure 20: Forces driving competition in the generics market in Mexico, 2021
Figure 21: Drivers of buyer power in the generics market in Mexico, 2021
Figure 22: Drivers of supplier power in the generics market in Mexico, 2021
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2021
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2021
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2021
Figure 26: United States generics market value: $ billion, 2016-21
Figure 27: United States generics market volume: %, 2016-21
Figure 28: United States generics market geography segmentation: % share, by value, 2021
Figure 29: United States generics market value forecast: $ billion, 2021-26
Figure 30: United States generics market volume forecast: %, 2021-26
Figure 31: Forces driving competition in the generics market in the United States, 2021
Figure 32: Drivers of buyer power in the generics market in the United States, 2021
Figure 33: Drivers of supplier power in the generics market in the United States, 2021
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2021
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2021
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2021

Report Title: North America (NAFTA) Generics Market Summary, Competitive Analysis and Forecast, 2017-2026


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM